Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.850
0.00 (0.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Fulcrum Therapeutics stock have an average target of 7.63, with a low estimate of 2.00 and a high estimate of 15. The average target predicts an increase of 98.18% from the current stock price of 3.85.
Analyst Consensus: Hold
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
The average analyst rating for Fulcrum Therapeutics stock from 9 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 6 | 6 | 6 | 6 | 6 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | +3.90% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $4 | Hold | Reiterates | $4 | +3.90% | Nov 14, 2024 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $15 → $4 | Buy → Hold | Downgrades | $15 → $4 | +3.90% | Sep 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $17 → $4 | Strong Buy → Hold | Downgrades | $17 → $4 | +3.90% | Sep 13, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $4 | Buy → Hold | Downgrades | $4 | +3.90% | Sep 12, 2024 |
Financial Forecast
Revenue This Year
82.01M
from 2.81M
Increased by 2,823.78%
Revenue Next Year
n/a
from 82.01M
EPS This Year
-0.23
from -1.59
EPS Next Year
-1.33
from -0.23
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 87.0M | n/a | 83.8M | |||
| Avg | 82.0M | n/a | 23.0M | |||
| Low | 78.4M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3,000.6% | - | - | |||
| Avg | 2,823.8% | - | - | |||
| Low | 2,695.0% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.08 | -0.85 | -1.05 | |||
| Avg | -0.23 | -1.33 | -1.68 | |||
| Low | -0.56 | -2.78 | -3.58 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.